Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Changes in PYY concentrations were examined in obese patients after bariatric surgery and compared to healthy controls.
|
30639417 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of Neuropeptide Y and Peptide YY in the Development of Obesity via Gut-brain Axis.
|
30678628 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
As PYY analogs are under development for treatment of obesity, we aimed to clarify the relationship between PYY and bone mass.
|
31306808 |
2019 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Peptide-YY (PYY) and Glucagon-Like Peptide-1 (GLP-1) play important roles in the regulation of food intake and insulin secretion, and are of translational interest in the field of obesity and diabetes.
|
29311617 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, the current review aims to compile, evaluate and summarise current knowledge on PYY, with particular emphasis on obesity and diabetes treatment, and the importance of specific Y receptor interactions for this.
|
29412828 |
2018 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, prebiotics influence metabolism, and in obesity they increase the expression of anorexigenic gut hormones such as peptide tyrosine tyrosine, glucagon-like peptide 1 and leptin, as well as decrease levels of orexigenic hormones such as ghrelin.
|
29883788 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
FFAs are candidate drug targets for increasing the secretion of intestinal hormones such as glucagon-like peptide-1 and peptide YY as potential new treatments for type 2 diabetes and obesity.
|
29688303 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In recent years peptide YY (PYY) has attracted attention within the area of diabetes and obesity due to its involvement in food intake regulation and glucose homeostasis.
|
30399314 |
2018 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
GLP-1 and PYY are higher during the light cycle in LEAN animals and AMY is higher in the OBESE group throughout the light/dark cycle.
|
29191090 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PYY and GLP-1 are implicated in regulation of gut motility, food intake and insulin secretion, and are of great interest regarding obesity and type 2 diabetes.
|
27405092 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gastrointestinal peptides such as peptide YY (PYY) can regulate appetite, which is relevant to the study of obesity.
|
28626523 |
2017 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, adiponectin and omentin from subcutaneous fat displayed correlations with decreased obesity and increased insulin sensitivity while visfatin showed an association with serum PYY and weight gain.
|
25453978 |
2014 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
RESEARCH DESIGN AND METHODS We studied 35 monozygotic (MZ) and 75 dizygotic (DZ) twin pairs (discordant and concordant for obesity) to determine the heritability of glucagon-like peptide 1 (GLP-1) responses to an oral glucose tolerance test (OGTT) and the influence of acquired obesity to GLP-1, glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) during OGTT or meal test.
|
23990519 |
2014 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
The discovery of this alternative circuit that regulates ingestive behavior without inducing taste aversion may open the possibility of a therapeutic application of PYY for the treatment of obesity via direct oral application.
|
24259562 |
2013 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Functional genetic variation at the PYY locus influences multiple heritable metabolic syndrome traits, likely conferring susceptibility to obesity and subsequent cardiorenal disease.
|
19820027 |
2009 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
To verify whether peptide YY (PYY) and its Y2 receptor (Y2R) gene variants can be associated with obesity or hypertension or both in a cohort of obese children and adolescents.
|
18622237 |
2008 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
PYY, along with few other gut hormones, has been suggested as a potential therapeutic agent for obesity.
|
18441153 |
2008 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to assess whether low fasting and postprandial PYY secretion is an early defect, potentially promoting the development of obesity and T2D, and whether it is modified by macronutrient content.
|
18317469 |
2008 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results provide evidence of association for NPY2R and PYY gene variants with obesity and none for PPY variants.
|
17235527 |
2007 |
Obesity
|
0.400 |
Biomarker
|
disease |
CTD_human |
A PYY Q62P variant linked to human obesity.
|
16368708 |
2006 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together, these results are the first to support that rare sequence variants within PYY can influence human susceptibility to obesity.
|
16368708 |
2006 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the human PYY and Y2 receptor genes may contribute to the development of obesity.
|
16756746 |
2006 |
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, these findings suggest that low circulating levels of PYY could contribute to hyperinsulinemia and insulin resistance, and possibly contribute to subsequent development of obesity and type 2 diabetes.
|
17045646 |
2006 |
Obesity
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found no association to obesity for the PYY Arg72Thr polymorphism, which is located nearby the essential carboxy terminal.
|
16331299 |
2006 |
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that modulating the release of endogenous satiety factors, such as PYY, through alteration of specific diet constituents could provide a rational therapy for obesity.
|
16950139 |
2006 |